The project has the scope to provide EU with a self sustainable and independent ability to discover, develop and manufacture vaccines and monoclonal antibodies against infectious diseases of epidemic and pandemic potential.
The EVH project contributes to the development of an agreed set of pandemic-prototype vaccines and scalable technologies through a consortium including leading EU organisations directly involved in vaccine development and in charge of pandemic preparedness in their own countries, ensuring effective coordination of national vaccine research programs. EVH aligns with the current international consensus on pandemic-vaccine development, leveraging insights from existing prototypes to enable the rapid selection and deployment of the most suitable vaccine candidates in an emerging pandemic.
From prototype design to clinical applications, the EVH drives innovation, enhances clinical evaluation capacities, and coordinate efforts with manufacturers while optimizing the digitalization of vaccine design and distribution processes. EVH aims thus not only to create a reactive R&D system and knowledge hub linking powerful leading research institutions, but also initiate vaccine-development projects, refining relevant processes and procedures within its framework. The focus is on a select group of pathogens deemed critical for pandemic preparedness.
EVH Facts
Topic: EU4H-2024-PJ-01-1
Total project cost: €169.992.330
EC contribution: €101.995.398
Duration: 4 years (1st March 2025-28th February 2029)
Coordinator Entity: Sclavo Vaccines Association (IT)
Partners: 11 Beneficiaries, 12 Affiliated Entities and 1 Associated Partner from 7 European countries
Contact: evhproject@sclavo.org
EVH STRATEGY
EVH is organised around 4 Pillars, each supporting key activities and infrastructures of the vaccine development pipeline:
🔎 Pillar 1: Discovery, led by FBS
🔬 Pillar 2: Preclinical Studies, led by Institut Pasteur
🏥 Pillar 3: Clinical Studies, led by Vaccinopolis
🧪 Pillar 4: Regulation & Manufacturing, led by DZIF & ZEPAI.
In the event of pandemic, each pillar will set up and implement the platforms necessary for rapid vaccine development. EVH will engage and reinforce the complete ecosystem of European industry and academia, promoting collaborations and the exchange of know-how and projects.
EVH PARTNERSHIP
 |
Sclavo Vaccines Association – SVA (IT) |
 |
Fondazione Biotecnopolo di Siena – FBS (IT) |
 |
Institut Pasteur – IP (FR) |
 |
Universiteit Antwerpen – Vaccinopolis (BE) |
 |
Deutsches Zentrum fur Infektionsforschung – DZIF (DE) |
 |
Bundesinstitut für Impfstoffe und Biomedizinische Arzneimittel – ZEPAI (DE) |
 |
Academisch Ziekenhuis Leiden – LUMC (NL) |
 |
Université libre de Bruxelles – ULB (BE) |
 |
Folkehelseinstituttet – NIPH (NO) |
 |
Università degli Studi di Siena – UNISI (IT) |
 |
Instituto de Biologia Experimental e Tecnologica – iBET (PT) |
Affiliated Entities
Fondazione Biotecnopolo di Siena
Instituto Zooprofilattico Sperimentale delle Venezie (IT)
Institut Pasteur
Infrastructure Nationale en Biologie et Santé– Commissariat à l’énergie atomique et aux energies alternatives (FR)
Institut national de la santé et de la recherche médicale (FR)
Deutsches Zenturm fur Infektionsforschung
Philipps Universität Marburg (DE)
Helmholtz Zentrum München (DE)
Helmholtz Centre for Infection Research (DE)
Ludwig-maximilians-Universitaet München (DE)
Stiftung Teirärztliche Hochschule Hannover (DE)
Technische Universität München (DE)
Universitätsklinikum Köln Aör (DE)
Universitätsklinikum Hamburg Eppensorf (DE)
Eberhard Karls Univeristät Tübingen (DE)
Associated partner
Pasteur Network (FR) (IP Associated partner)
Others
VisMederi s.r.l. (IT) (FBS Subcontractor)
Reithera s.r.l. (IT) (FBS Subcontractor)
Coordinator contact: evhproject@sclavo.org
Follow the project on
“Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them”
